AVCN.F Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Avicanna Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.21 |
| 52 Week High | CA$0.53 |
| 52 Week Low | CA$0.17 |
| Beta | 1.54 |
| 1 Month Change | -17.69% |
| 3 Month Change | -49.13% |
| 1 Year Change | -0.97% |
| 3 Year Change | -71.50% |
| 5 Year Change | n/a |
| Change since IPO | -92.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| AVCN.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 17.5% | 0.4% | 1.2% |
| 1Y | -1.0% | 17.1% | 20.6% |
Return vs Industry: AVCN.F underperformed the US Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: AVCN.F underperformed the US Market which returned 20.6% over the past year.
Price Volatility
| AVCN.F volatility | |
|---|---|
| AVCN.F Average Weekly Movement | 21.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVCN.F's share price has been volatile over the past 3 months.
Volatility Over Time: AVCN.F's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 87 | Aras Azadian | www.avicanna.com |
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
Avicanna Inc. Fundamentals Summary
| AVCN.F fundamental statistics | |
|---|---|
| Market cap | US$19.61m |
| Earnings (TTM) | -US$5.28m |
| Revenue (TTM) | US$16.07m |
1.2x
P/S Ratio-3.7x
P/E RatioIs AVCN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AVCN.F income statement (TTM) | |
|---|---|
| Revenue | CA$22.07m |
| Cost of Revenue | CA$13.00m |
| Gross Profit | CA$9.07m |
| Other Expenses | CA$16.32m |
| Earnings | -CA$7.25m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | 41.09% |
| Net Profit Margin | -32.86% |
| Debt/Equity Ratio | 19.8% |
How did AVCN.F perform over the long term?
See historical performance and comparison